This is a table of type unigram and their frequencies. Use it to search & browse the list to learn more about your study carrel.
| unigram | frequency |
|---|---|
| covid | 200 |
| patients | 189 |
| il | 78 |
| risk | 73 |
| sars | 68 |
| cov | 66 |
| study | 66 |
| cord | 64 |
| disease | 62 |
| severe | 62 |
| treatment | 55 |
| psoriasis | 55 |
| infection | 53 |
| dermatology | 49 |
| patient | 49 |
| pandemic | 48 |
| authors | 47 |
| i | 47 |
| data | 45 |
| clinical | 43 |
| skin | 43 |
| safety | 41 |
| care | 39 |
| placebo | 38 |
| may | 38 |
| viral | 38 |
| jaad | 37 |
| journal | 36 |
| anti | 35 |
| date | 34 |
| trials | 34 |
| antibody | 34 |
| also | 34 |
| coronavirus | 34 |
| title | 33 |
| key | 33 |
| doi | 33 |
| id | 32 |
| acad | 32 |
| doc | 32 |
| uid | 32 |
| dermatol | 32 |
| sha | 32 |
| results | 32 |
| phase | 31 |
| lesions | 30 |
| associated | 30 |
| nan | 30 |
| controlled | 29 |
| like | 29 |
| teledermatology | 28 |
| moderate | 28 |
| ustekinumab | 27 |
| cases | 27 |
| efficacy | 27 |
| contact | 27 |
| rtis | 27 |
| use | 26 |
| potential | 26 |
| including | 26 |
| infections | 26 |
| non | 26 |
| analysis | 26 |
| medical | 26 |
| visits | 26 |
| dermatitis | 25 |
| trial | 24 |
| respiratory | 24 |
| randomized | 23 |
| drugs | 23 |
| reported | 23 |
| infectious | 22 |
| dr | 22 |
| hospital | 22 |
| response | 22 |
| population | 22 |
| increased | 22 |
| outcomes | 22 |
| compared | 22 |
| studies | 22 |
| varicella | 21 |
| used | 21 |
| table | 21 |
| included | 21 |
| review | 20 |
| pneumonia | 20 |
| factor | 19 |
| diseases | 19 |
| two | 19 |
| transmission | 19 |
| age | 18 |
| biologic | 18 |
| health | 18 |
| adalimumab | 18 |
| inflammatory | 18 |
| ild | 17 |
| interleukin | 17 |
| double | 17 |
| janssen | 17 |
| specific | 17 |
| type | 17 |
| acute | 17 |
| ace | 17 |
| based | 17 |
| cells | 16 |
| biologics | 16 |
| case | 16 |
| virus | 16 |
| biobadaderm | 16 |
| inhibitors | 16 |
| due | 16 |
| however | 16 |
| time | 16 |
| cutaneous | 16 |
| immune | 15 |
| outbreak | 15 |
| systemic | 15 |
| test | 15 |
| therapies | 15 |
| positive | 15 |
| psoriatic | 15 |
| blind | 15 |
| conducted | 14 |
| cohort | 14 |
| available | 14 |
| manuscript | 14 |
| performed | 14 |
| monoclonal | 14 |
| april | 14 |
| year | 14 |
| therapy | 14 |
| novartis | 14 |
| hospitalized | 14 |
| pfizer | 14 |
| urtis | 14 |
| healthcare | 13 |
| group | 13 |
| companies | 13 |
| participated | 13 |
| cytokines | 13 |
| virtual | 13 |
| abbvie | 13 |
| prospective | 13 |
| person | 13 |
| plaque | 13 |
| active | 13 |
| students | 13 |
| will | 13 |
| meta | 13 |
| important | 13 |
| human | 13 |
| current | 12 |
| interest | 12 |
| masks | 12 |
| agents | 12 |
| rash | 12 |
| publication | 12 |
| lilly | 12 |
| high | 12 |
| systematic | 12 |
| infected | 12 |
| briakinumab | 12 |
| hs | 12 |
| incidence | 12 |
| md | 12 |
| program | 12 |
| findings | 12 |
| control | 12 |
| programs | 12 |
| evidence | 12 |
| chronic | 12 |
| significantly | 12 |
| occupational | 12 |
| immunosuppressants | 11 |
| need | 11 |
| following | 11 |
| therefore | 11 |
| one | 11 |
| testing | 11 |
| autoimmune | 11 |
| pharma | 11 |
| increase | 11 |
| speaker | 11 |
| include | 11 |
| without | 11 |
| era | 11 |
| symptoms | 11 |
| celgene | 11 |
| overall | 11 |
| randomised | 11 |
| application | 11 |
| msd | 11 |
| whether | 11 |
| value | 11 |
| leo | 11 |
| arthritis | 11 |
| jaki | 11 |
| bias | 11 |
| facial | 11 |
| years | 11 |
| guselkumab | 11 |
| personal | 11 |
| treated | 11 |
| receiving | 11 |
| formaldehyde | 11 |
| present | 11 |
| among | 11 |
| groups | 10 |
| mg | 10 |
| diagnosis | 10 |
| consultant | 10 |
| treatments | 10 |
| jak | 10 |
| dermatologic | 10 |
| rd | 10 |
| although | 10 |
| hydroxychloroquine | 10 |
| syndrome | 10 |
| evaluation | 10 |
| equipment | 10 |
| dose | 10 |
| ci | 10 |
| national | 10 |
| mh | 10 |
| pcr | 10 |
| described | 10 |
| outpatient | 10 |
| expression | 10 |
| similar | 10 |
| days | 10 |
| residency | 10 |
| related | 10 |
| analyses | 10 |
| using | 9 |
| management | 9 |
| number | 9 |
| oral | 9 |
| needed | 9 |
| heterogeneity | 9 |
| sign | 9 |
| iii | 9 |
| might | 9 |
| spread | 9 |
| manifestation | 9 |
| icu | 9 |
| chilblains | 9 |
| possible | 9 |
| suggests | 9 |
| first | 9 |
| risankizumab | 9 |
| men | 9 |
| hns | 9 |
| sexual | 9 |
| report | 9 |
| likely | 9 |
| cell | 9 |
| respectively | 9 |
| role | 9 |
| spanish | 9 |
| period | 9 |
| physicians | 9 |
| published | 9 |
| even | 9 |
| webinar | 9 |
| products | 9 |
| necrosis | 9 |
| series | 9 |
| identified | 9 |
| work | 9 |
| week | 9 |
| addition | 9 |
| home | 9 |
| adverse | 8 |
| lrtis | 8 |
| observed | 8 |
| part | 8 |
| events | 8 |
| hospitalization | 8 |
| manifestations | 8 |
| practice | 8 |
| regarding | 8 |
| negative | 8 |
| rashes | 8 |
| provide | 8 |
| weeks | 8 |
| different | 8 |
| antagonists | 8 |
| course | 8 |
| seen | 8 |
| exanthem | 8 |
| order | 8 |
| lower | 8 |
| within | 8 |
| given | 8 |
| particularly | 8 |
| baldness | 8 |
| alopecia | 8 |
| access | 8 |
| residents | 8 |
| interferon | 8 |
| mask | 8 |
| common | 8 |
| pattern | 8 |
| necessary | 8 |
| ischemic | 8 |
| tnf | 8 |
| many | 8 |
| showed | 8 |
| new | 8 |
| protective | 8 |
| protein | 7 |
| impact | 7 |
| cytokine | 7 |
| consider | 7 |
| fda | 7 |
| service | 7 |
| aga | 7 |
| via | 7 |
| support | 7 |
| event | 7 |
| items | 7 |
| us | 7 |
| risks | 7 |
| workers | 7 |
| tumor | 7 |
| individuals | 7 |
| higher | 7 |
| zoster | 7 |
| severity | 7 |
| issue | 7 |
| cilag | 7 |
| strategies | 7 |
| death | 7 |
| factors | 7 |
| previous | 7 |
| financial | 7 |
| early | 7 |
| continue | 7 |
| dermatologists | 7 |
| drug | 7 |
| large | 7 |
| limitations | 7 |
| almirall | 7 |
| previously | 7 |
| lung | 7 |
| additional | 7 |
| read | 7 |
| production | 7 |
| old | 7 |
| ed | 7 |
| kits | 7 |
| tests | 7 |
| surgical | 7 |
| main | 7 |
| exposure | 7 |
| others | 7 |
| demonstrated | 7 |
| rotations | 7 |
| information | 7 |
| tract | 7 |
| department | 7 |
| questions | 7 |
| host | 7 |
| total | 7 |
| face | 7 |
| immunomodulators | 6 |
| polyethylene | 6 |
| american | 6 |
| diagnoses | 6 |
| loss | 6 |
| approved | 6 |
| single | 6 |
| clinic | 6 |
| identify | 6 |
| prior | 6 |
| ifn | 6 |
| currently | 6 |
| international | 6 |
| acro | 6 |
| herpes | 6 |
| concern | 6 |
| rare | 6 |
| rcts | 6 |
| abbott | 6 |
| mild | 6 |
| development | 6 |
| registry | 6 |
| atopic | 6 |
| www | 6 |
| rate | 6 |
| sex | 6 |
| general | 6 |
| male | 6 |
| ii | 6 |
| recent | 6 |
| classic | 6 |
| gabrin | 6 |
| biological | 6 |
| typically | 6 |
| antibodies | 6 |
| androgenetic | 6 |
| epidemic | 6 |
| found | 6 |
| prolonged | 6 |
| unknown | 6 |
| day | 6 |
| editor | 6 |
| status | 6 |
| significant | 6 |
| useful | 6 |
| article | 6 |
| interrupted | 6 |
| nieto | 6 |
| predictive | 6 |
| limited | 6 |
| baricitinib | 6 |
| acted | 6 |
| statement | 6 |
| novel | 6 |
| known | 6 |
| provider | 6 |
| low | 6 |
| preferred | 6 |
| respirators | 6 |
| protect | 6 |
| fernandez | 6 |
| pernio | 6 |
| hair | 6 |
| term | 6 |
| versus | 6 |
| asynchronous | 6 |
| applicants | 6 |
| cellulitis | 6 |
| required | 6 |
| suppurativa | 5 |
| staff | 5 |
| vaccine | 5 |
| know | 5 |
| experience | 5 |
| march | 5 |
| long | 5 |
| local | 5 |
| pharmacokinetics | 5 |
| concomitant | 5 |
| less | 5 |
| center | 5 |
| messages | 5 |
| conclusion | 5 |
| concerns | 5 |
| reactions | 5 |
| best | 5 |
| interviews | 5 |
| ratio | 5 |
| meet | 5 |
| recommendation | 5 |
| nasal | 5 |
| selected | 5 |
| dermatoses | 5 |
| greater | 5 |
| elevated | 5 |
| often | 5 |
| primary | 5 |
| rather | 5 |
| panelists | 5 |
| effect | 5 |
| involved | 5 |
| reactivation | 5 |
| influenza | 5 |
| org | 5 |
| comorbidities | 5 |
| objective | 5 |
| direct | 5 |
| inhibitor | 5 |
| interstitial | 5 |
| tildrakizumab | 5 |
| reports | 5 |
| https | 5 |
| away | 5 |
| rectal | 5 |
| suggest | 5 |
| particular | 5 |
| prophylaxis | 5 |
| ncov | 5 |
| allergic | 5 |
| hidradenitis | 5 |
| hours | 5 |
| furthermore | 5 |
| prevalence | 5 |
| characteristics | 5 |
| office | 5 |
| understand | 5 |
| funnel | 5 |
| problems | 5 |
| especially | 5 |
| responses | 5 |
| permitted | 5 |
| confirmed | 5 |
| director | 5 |
| now | 5 |
| rapid | 5 |
| absent | 5 |
| global | 5 |
| jennifer | 5 |
| compare | 5 |
| caution | 5 |
| system | 5 |
| resources | 5 |
| confirm | 5 |
| susceptibility | 5 |
| considered | 5 |
| healthy | 5 |
| retrospective | 5 |
| clinicians | 5 |
| ventilator | 5 |
| vs | 5 |
| history | 5 |
| sponsored | 5 |
| activity | 5 |
| experiencing | 5 |
| setting | 5 |
| research | 5 |
| rates | 5 |
| pharmaceutical | 5 |
| word | 5 |
| extensive | 5 |
| process | 5 |
| worse | 5 |
| follow | 5 |
| despite | 5 |
| reply | 5 |
| base | 5 |
| multicenter | 5 |
| jimenez | 5 |
| small | 5 |
| ppe | 4 |
| theoretical | 4 |
| outbreaks | 4 |
| commonly | 4 |
| received | 4 |
| served | 4 |
| quality | 4 |
| advice | 4 |
| glycols | 4 |
| resulting | 4 |
| minutes | 4 |
| zero | 4 |
| rna | 4 |
| co | 4 |
| relevant | 4 |
| acral | 4 |
| gastrointestinal | 4 |
| paper | 4 |
| evaluate | 4 |
| life | 4 |
| significance | 4 |
| toxicities | 4 |
| colleagues | 4 |
| induction | 4 |
| mab | 4 |
| contribute | 4 |
| defined | 4 |
| precautions | 4 |
| target | 4 |
| real | 4 |
| frequencies | 4 |
| fever | 4 |
| reporting | 4 |
| occur | 4 |
| reticularis | 4 |
| making | 4 |
| asymptomatic | 4 |
| procedure | 4 |
| robust | 4 |
| implications | 4 |
| vaccines | 4 |
| exact | 4 |
| balding | 4 |
| derived | 4 |
| universitario | 4 |
| examined | 4 |
| manufacture | 4 |
| community | 4 |
| state | 4 |
| morbidities | 4 |
| scores | 4 |
| amgen | 4 |
| syphilis | 4 |
| since | 4 |
| across | 4 |
| reviewed | 4 |
| rivera | 4 |
| surgery | 4 |
| maintenance | 4 |
| either | 4 |
| change | 4 |
| herpetic | 4 |
| absence | 4 |
| growth | 4 |
| guidance | 4 |
| spain | 4 |
| inflammation | 4 |
| services | 4 |
| practices | 4 |
| approval | 4 |
| verona | 4 |
| polypropylene | 4 |
| reference | 4 |
| danielle | 4 |
| cancelled | 4 |
| issues | 4 |
| states | 4 |
| assess | 4 |
| sensitivity | 4 |
| resins | 4 |
| mucosa | 4 |
| crs | 4 |
| herrera | 4 |
| multiple | 4 |
| livedo | 4 |
| fear | 4 |
| price | 4 |
| pre | 4 |
| comment | 4 |
| dermatologist | 4 |
| medication | 4 |
| protection | 4 |
| policies | 4 |
| william | 4 |
| prevent | 4 |
| agree | 4 |
| caused | 4 |
| taken | 4 |
| peterson | 4 |
| sstis | 4 |
| acne | 4 |
| subsequent | 4 |
| comparing | 4 |
| hcws | 4 |
| japanese | 4 |
| blood | 4 |
| exanthems | 4 |
| portal | 4 |
| patterns | 4 |
| moreover | 4 |
| academy | 4 |
| cause | 4 |
| address | 4 |
| vesicles | 4 |
| delivery | 4 |
| collection | 4 |
| th | 4 |
| must | 4 |
| letter | 4 |
| king | 4 |
| wear | 4 |
| literature | 4 |
| damsky | 4 |
| help | 4 |
| lesion | 4 |
| descriptive | 4 |
| vesicular | 4 |
| evisits | 4 |
| preventing | 4 |
| members | 4 |
| inclusion | 4 |
| wuhan | 4 |
| occurred | 4 |
| considerations | 4 |
| androgen | 4 |
| prevention | 4 |
| six | 4 |
| institution | 4 |
| video | 4 |
| methods | 4 |
| presented | 4 |
| decision | 4 |
| specificity | 4 |
| induced | 4 |
| guidelines | 4 |
| opportunities | 4 |
| articles | 4 |
| collected | 4 |
| preliminary | 4 |
| emergency | 4 |
| statistical | 4 |
| hand | 4 |
| storm | 4 |
| correction | 4 |
| mediated | 4 |
| brett | 4 |
| per | 4 |
| sir | 4 |
| simplex | 4 |
| toes | 4 |
| textile | 4 |
| medicine | 4 |
| telemedicine | 4 |
| comparison | 4 |
| diagnostic | 4 |
| hypothesize | 4 |
| updated | 4 |
| immunosuppressive | 4 |
| classification | 4 |
| lr | 3 |
| indicated | 3 |
| going | 3 |
| preference | 3 |
| recommend | 3 |
| consensus | 3 |
| prisma | 3 |
| asymmetric | 3 |
| effective | 3 |
| tissue | 3 |
| molecular | 3 |
| adults | 3 |
| accept | 3 |
| treat | 3 |
| chen | 3 |
| dental | 3 |
| intercourse | 3 |
| divided | 3 |
| velasco | 3 |
| shelters | 3 |
| percentages | 3 |
| probability | 3 |
| coagulation | 3 |
| tested | 3 |
| recommended | 3 |
| encounters | 3 |
| benefit | 3 |
| preservative | 3 |
| neck | 3 |
| acutely | 3 |
| secondary | 3 |
| applications | 3 |
| blasco | 3 |
| nasopharyngitis | 3 |
| individual | 3 |
| become | 3 |
| consistent | 3 |
| hypothesized | 3 |
| relationships | 3 |
| reduces | 3 |
| require | 3 |
| telephone | 3 |
| sample | 3 |
| plot | 3 |
| difference | 3 |
| respondents | 3 |
| admitted | 3 |
| landscape | 3 |
| exposed | 3 |
| critical | 3 |
| lack | 3 |
| thank | 3 |
| evolving | 3 |
| reassuring | 3 |
| team | 3 |
| contagion | 3 |
| forward | 3 |
| association | 3 |
| died | 3 |
| english | 3 |
| reverse | 3 |
| believe | 3 |
| provided | 3 |
| elsewhere | 3 |
| fact | 3 |
| raising | 3 |
| transmitted | 3 |
| multicentre | 3 |
| revealed | 3 |
| vilar | 3 |
| shedding | 3 |
| pioneer | 3 |
| maintaining | 3 |
| create | 3 |
| strongly | 3 |
| evaluated | 3 |
| subjects | 3 |
| month | 3 |
| speaking | 3 |
| still | 3 |
| sensitive | 3 |
| sites | 3 |
| except | 3 |
| brazil | 3 |
| appropriate | 3 |
| existing | 3 |
| open | 3 |
| combined | 3 |
| erythematous | 3 |
| cd | 3 |
| according | 3 |
| quijano | 3 |
| pressure | 3 |
| administration | 3 |
| contributed | 3 |
| true | 3 |
| routes | 3 |
| late | 3 |
| starting | 3 |
| limit | 3 |
| registries | 3 |
| reaction | 3 |
| least | 3 |
| analyzed | 3 |
| separate | 3 |
| recruitment | 3 |
| categories | 3 |
| requests | 3 |
| conduct | 3 |
| measures | 3 |
| marzano | 3 |
| comprehensive | 3 |
| collaboration | 3 |
| subject | 3 |
| donoso | 3 |
| anal | 3 |
| screening | 3 |
| susceptible | 3 |
| informed | 3 |
| ip | 3 |
| latest | 3 |
| viewers | 3 |
| feces | 3 |
| disparities | 3 |
| herpesvirus | 3 |
| insufficient | 3 |
| kinase | 3 |
| transient | 3 |
| make | 3 |
| lastly | 3 |
| remain | 3 |
| able | 3 |
| possibility | 3 |
| burgos | 3 |
| epithelia | 3 |
| potentially | 3 |
| epidemiologic | 3 |
| cauhe | 3 |
| pilot | 3 |
| etanercept | 3 |
| question | 3 |
| assessing | 3 |
| visit | 3 |
| clinics | 3 |
| proven | 3 |
| highlight | 3 |
| techniques | 3 |
| reduce | 3 |
| criteria | 3 |
| original | 3 |
| ill | 3 |
| kg | 3 |
| electronic | 3 |
| wambier | 3 |
| nationwide | 3 |
| upadacitinib | 3 |
| expected | 3 |
| grade | 3 |
| llamas | 3 |
| finally | 3 |
| calculate | 3 |
| place | 3 |
| saliva | 3 |
| ucb | 3 |
| cold | 3 |
| four | 3 |
| way | 3 |
| ab | 3 |
| neither | 3 |
| addressed | 3 |
| people | 3 |
| hence | 3 |
| wu | 3 |
| populations | 3 |
| find | 3 |
| mychart | 3 |
| version | 3 |
| highest | 3 |
| growing | 3 |
| prepare | 3 |
| nasopharyngeal | 3 |
| homeless | 3 |
| qw | 3 |
| action | 3 |
| areas | 3 |
| certain | 3 |
| room | 3 |
| cochrane | 3 |
| standard | 3 |
| majority | 3 |
| downregulated | 3 |
| upper | 3 |
| peh | 3 |
| great | 3 |
| delivered | 3 |
| steps | 3 |
| mechanism | 3 |
| descalzo | 3 |
| three | 3 |
| future | 3 |
| head | 3 |
| responsibility | 3 |
| receive | 3 |
| ortega | 3 |
| receptor | 3 |
| carretero | 3 |
| administered | 3 |
| conditions | 3 |
| specifically | 3 |
| red | 3 |
| targeted | 3 |
| facilities | 3 |
| resident | 3 |
| result | 3 |
| show | 3 |
| just | 3 |
| contacted | 3 |
| degradation | 3 |
| expressed | 3 |
| noted | 3 |
| promotes | 3 |
| medications | 3 |
| attendings | 3 |
| aged | 3 |
| managing | 3 |
| conventional | 3 |
| epithelial | 3 |
| considering | 3 |
| urgent | 3 |
| constant | 3 |
| context | 3 |
| aware | 3 |
| determine | 3 |
| submit | 3 |
| light | 3 |
| well | 3 |
| observational | 3 |
| taking | 3 |
| pathogens | 3 |
| alejo | 3 |
| poor | 3 |
| microbe | 3 |
| five | 3 |
| employees | 3 |
| right | 3 |
| anxiety | 3 |
| reviews | 3 |
| effects | 3 |
| treating | 3 |
| questionnaires | 3 |
| chilblain | 3 |
| presence | 3 |
| public | 3 |
| profile | 3 |
| air | 3 |
| pulmonary | 3 |
| implementation | 3 |
| decrease | 3 |
| united | 3 |
| acd | 3 |
| characterization | 3 |
| differentiation | 3 |
| randomly | 3 |
| unilateral | 3 |
| detected | 3 |
| fecal | 3 |
| presentation | 3 |
| clearance | 3 |
| focused | 3 |
| cancer | 3 |
| functions | 2 |
| xdr | 2 |
| tan | 2 |
| fold | 2 |
| bowel | 2 |
| diego | 2 |
| phk | 2 |
| duplicates | 2 |
| phd | 2 |
| strength | 2 |
| adoption | 2 |
| immunity | 2 |
| possibly | 2 |
| past | 2 |
| dirk | 2 |
| cavanaugh | 2 |
| subcutaneous | 2 |
| invasive | 2 |
| mice | 2 |
| suited | 2 |
| widely | 2 |
| private | 2 |
| plasma | 2 |
| peroxides | 2 |
| discontinuing | 2 |
| utilization | 2 |
| particle | 2 |
| differential | 2 |
| suicide | 2 |
| therapeutic | 2 |
| racial | 2 |
| model | 2 |
| mouth | 2 |
| sanitizer | 2 |
| kihj | 2 |
| removal | 2 |
| nnunjora | 2 |
| ministry | 2 |
| label | 2 |
| hussey | 2 |
| incidences | 2 |
| education | 2 |
| building | 2 |
| weighted | 2 |
| spondylitis | 2 |
| average | 2 |
| actually | 2 |
| resembling | 2 |
| every | 2 |
| along | 2 |
| fewer | 2 |
| costs | 2 |
| raised | 2 |
| percentage | 2 |
| later | 2 |
| longer | 2 |
| crisis | 2 |
| match | 2 |
| histological | 2 |
| jane | 2 |
| virulent | 2 |
| school | 2 |
| raises | 2 |
| recur | 2 |
| indications | 2 |
| letters | 2 |
| learned | 2 |
| macrophage | 2 |
| epidemiology | 2 |
| st | 2 |
| hygiene | 2 |
| concerning | 2 |
| power | 2 |
| extra | 2 |
| confidence | 2 |
| world | 2 |
| attributed | 2 |
| mk | 2 |
| supported | 2 |
| antidrug | 2 |
| molecule | 2 |
| del | 2 |
| twnqr | 2 |
| haya | 2 |
| recognized | 2 |
| unique | 2 |
| university | 2 |
| initiated | 2 |
| denominators | 2 |
| serves | 2 |
| byproduct | 2 |
| welldefined | 2 |
| point | 2 |
| endocytosis | 2 |
| pathogenesis | 2 |
| inhibit | 2 |
| periods | 2 |
| counsel | 2 |
| discussed | 2 |
| kansal | 2 |
| indeed | 2 |
| calculated | 2 |
| fynxciwg | 2 |
| settings | 2 |
| exacerbated | 2 |
| hope | 2 |
| field | 2 |
| qd | 2 |
| combination | 2 |
| distribution | 2 |
| fourth | 2 |
| estrada | 2 |
| standardized | 2 |
| plywood | 2 |
| stable | 2 |
| predominantly | 2 |
| content | 2 |
| subgroup | 2 |
| seven | 2 |
| persistent | 2 |
| enhanced | 2 |
| records | 2 |
| promoted | 2 |
| adult | 2 |
| much | 2 |
| workplace | 2 |
| smith | 2 |
| immunotherapies | 2 |
| neera | 2 |
| italy | 2 |
| advocate | 2 |
| offer | 2 |
| scientific | 2 |
| bridge | 2 |
| prescribed | 2 |
| accounted | 2 |
| deteriorated | 2 |
| mellitus | 2 |
| interpretation | 2 |
| lebwohl | 2 |
| cte | 2 |
| hematuria | 2 |
| better | 2 |
| immediate | 2 |
| csf | 2 |
| approach | 2 |
| unequal | 2 |
| shown | 2 |
| doctors | 2 |
| listed | 2 |
| discussing | 2 |
| mention | 2 |
| progression | 2 |
| shelter | 2 |
| released | 2 |
| awareness | 2 |
| visual | 2 |
| autoxidation | 2 |
| vius | 2 |
| interval | 2 |
| azithromycin | 2 |
| tween | 2 |
| publications | 2 |
| eg | 2 |
| derivatives | 2 |
| outcome | 2 |
| cessation | 2 |
| array | 2 |
| times | 2 |
| peak | 2 |
| xa | 2 |
| interested | 2 |
| adequate | 2 |
| tumors | 2 |
| relative | 2 |
| done | 2 |
| gisondi | 2 |
| aid | 2 |
| assist | 2 |
| sandborn | 2 |
| isgcm | 2 |
| pubmed | 2 |
| resurface | 2 |
| chat | 2 |
| terms | 2 |
| utilizing | 2 |
| ry | 2 |
| creating | 2 |
| packaging | 2 |
| cheeks | 2 |
| fulltext | 2 |
| random | 2 |
| entire | 2 |
| fp | 2 |
| laboratory | 2 |
| stay | 2 |
| ongoing | 2 |
| fatality | 2 |
| stage | 2 |
| hypertension | 2 |
| sanitarios | 2 |
| hsiao | 2 |
| brazikumab | 2 |
| acosta | 2 |
| satisfaction | 2 |
| encourage | 2 |
| pjdedw | 2 |
| inhibition | 2 |
| theoretically | 2 |
| pl | 2 |
| dermatological | 2 |
| online | 2 |
| cancers | 2 |
| hiv | 2 |
| method | 2 |
| note | 2 |
| staining | 2 |
| shared | 2 |
| demonstrate | 2 |
| prove | 2 |
| grants | 2 |
| homelessness | 2 |
| routinely | 2 |
| botella | 2 |
| ionic | 2 |
| rt | 2 |
| major | 2 |
| pertinent | 2 |
| vdbk | 2 |
| serological | 2 |
| immunofluorescence | 2 |
| suggestive | 2 |
| advances | 2 |
| abscess | 2 |
| mucocutaneous | 2 |
| shifting | 2 |
| second | 2 |
| nose | 2 |
| differentiate | 2 |
| together | 2 |
| sometimes | 2 |
| continuing | 2 |
| editorial | 2 |
| range | 2 |
| guhan | 2 |
| suffered | 2 |
| assessment | 2 |
| amid | 2 |
| pceenwb | 2 |
| withdrawal | 2 |
| raef | 2 |
| directed | 2 |
| bnifxm | 2 |
| gateway | 2 |
| lpl | 2 |
| applies | 2 |
| named | 2 |
| nonwoven | 2 |
| line | 2 |
| sun | 2 |
| highlights | 2 |
| physician | 2 |
| challenge | 2 |
| cycle | 2 |
| productos | 2 |
| affecting | 2 |
| errors | 2 |
| cueva | 2 |
| shows | 2 |
| piel | 2 |
| academic | 2 |
| ankylosing | 2 |
| glycol | 2 |
| deaths | 2 |
| take | 2 |
| zi | 2 |
| yes | 2 |
| investigated | 2 |
| sufficient | 2 |
| nathan | 2 |
| weekly | 2 |
| intensive | 2 |
| yvbufnf | 2 |
| glandular | 2 |
| grant | 2 |
| suggested | 2 |
| justin | 2 |
| sought | 2 |
| reasons | 2 |
| category | 2 |
| july | 2 |
| author | 2 |
| apd | 2 |
| sclerosis | 2 |
| peri | 2 |
| fulfill | 2 |
| effort | 2 |
| recommendations | 2 |
| peset | 2 |
| yiv | 2 |
| wall | 2 |
| conference | 2 |
| post | 2 |
| vy | 2 |
| suffer | 2 |
| caucasian | 2 |
| pro | 2 |
| buoweg | 2 |
| qqdr | 2 |
| innovative | 2 |
| polyoxyethylenic | 2 |
| india | 2 |
| materials | 2 |
| notifications | 2 |
| minimize | 2 |
| nclk | 2 |
| biobank | 2 |
| types | 2 |
| remitting | 2 |
| generosity | 2 |
| soap | 2 |
| surfactants | 2 |
| plastics | 2 |
| frlr | 2 |
| older | 2 |
| moving | 2 |
| affect | 2 |
| centers | 2 |
| needs | 2 |
| margaret | 2 |
| finding | 2 |
| helper | 2 |
| challenges | 2 |
| typical | 2 |
| comparator | 2 |
| causes | 2 |
| plots | 2 |
| lessons | 2 |
| eruption | 2 |
| medicines | 2 |
| consultations | 2 |
| econsults | 2 |
| street | 2 |
| urticaria | 2 |
| scope | 2 |
| suspected | 2 |
| juan | 2 |
| aq | 2 |
| hepatitis | 2 |
| cough | 2 |
| conflict | 2 |
| ways | 2 |
| form | 2 |
| immunization | 2 |
| block | 2 |
| ultimma | 2 |
| presentations | 2 |
| vocation | 2 |
| avoids | 2 |
| frequency | 2 |
| samantha | 2 |
| involve | 2 |
| approximately | 2 |
| third | 2 |
| biogen | 2 |
| daily | 2 |
| sunlight | 2 |
| comments | 2 |
| superficial | 2 |
| asfqva | 2 |
| suffering | 2 |
| written | 2 |
| observations | 2 |
| embase | 2 |
| marginalized | 2 |
| interpreter | 2 |
| levels | 2 |
| collaborating | 2 |
| affected | 2 |
| decreased | 2 |
| supply | 2 |
| bacterial | 2 |
| marina | 2 |
| rp | 2 |
| isolation | 2 |
| recorded | 2 |
| borne | 2 |
| patel | 2 |
| ag | 2 |
| immunosuppressant | 2 |
| hcq | 2 |
| consideration | 2 |
| lupus | 2 |
| stratification | 2 |
| chinese | 2 |
| collaborated | 2 |
| natalia | 2 |
| understanding | 2 |
| medicamentos | 2 |
| injuries | 2 |
| end | 2 |
| regardless | 2 |
| adhesive | 2 |
| demonstrating | 2 |
| front | 2 |
| selection | 2 |
| phoenix | 2 |
| hypothesis | 2 |
| eventually | 2 |
| commentary | 2 |
| polymerase | 2 |
| mycobacterial | 2 |
| young | 2 |
| reschedule | 2 |
| sources | 2 |
| candidiasis | 2 |
| asymmetry | 2 |
| kels | 2 |
| lead | 2 |
| raw | 2 |
| excluded | 2 |
| essential | 2 |
| immunomodulator | 2 |
| accuracy | 2 |
| resolved | 2 |
| calcineurin | 2 |
| collated | 2 |
| seems | 2 |
| institute | 2 |
| level | 2 |
| leg | 2 |
| origin | 2 |
| hospitals | 2 |
| chemical | 2 |
| obtained | 2 |
| ears | 2 |
| start | 2 |
| respirator | 2 |
| unpaired | 2 |
| vlwlgp | 2 |
| swab | 2 |
| black | 2 |
| sana | 2 |
| began | 2 |
| carrascosa | 2 |
| fully | 2 |
| distributed | 2 |
| diga | 2 |
| stress | 2 |
| summarized | 2 |
| chain | 2 |
| student | 2 |
| underrepresented | 2 |
| preventive | 2 |
| something | 2 |
| surgeon | 2 |
| allergen | 2 |
| barrier | 2 |
| agency | 2 |
| burden | 2 |
| addressing | 2 |
| paid | 2 |
| frew | 2 |
| agencia | 2 |
| mar | 2 |
| detection | 2 |
| analyze | 2 |
| phenotype | 2 |
| traditional | 2 |
| rise | 2 |
| quite | 2 |
| called | 2 |
| receives | 2 |
| onset | 2 |
| bqw | 2 |
| self | 2 |
| critically | 2 |
| begg | 2 |
| deep | 2 |
| xsroivzj | 2 |
| strategy | 2 |
| beyond | 2 |
| allergenic | 2 |
| perspective | 2 |
| lasted | 2 |
| immunosuppression | 2 |
| median | 2 |
| rapidly | 2 |
| bbo | 2 |
| peggy | 2 |
| mers | 2 |
| half | 2 |
| clear | 2 |
| patricia | 2 |
| egvdvvtx | 2 |
| developing | 2 |
| ndan | 2 |
| kyla | 2 |
| components | 2 |
| highly | 2 |
| transcription | 2 |
| voyage | 2 |
| histopathology | 2 |
| means | 2 |
| irritant | 2 |
| egger | 2 |
| lj | 2 |
| council | 2 |
| project | 2 |
| rheumatologic | 2 |
| presenting | 2 |
| aimed | 2 |
| symptomatic | 2 |
| goal | 2 |
| gomez | 2 |
| estimated | 2 |
| led | 2 |
| female | 2 |
| irb | 2 |
| consulted | 2 |
| meant | 2 |
| cscc | 2 |
| atypical | 2 |
| methotrexate | 2 |
| thrombosis | 2 |
| surrounding | 2 |
| minorities | 2 |
| endothelial | 2 |
| john | 2 |
| liposuction | 2 |
| assembly | 2 |
| delayed | 2 |
| release | 2 |
| bmi | 2 |
| stop | 2 |
| worldwide | 2 |
| professionals | 2 |
| profiling | 2 |
| caring | 2 |
| serious | 2 |
| resulted | 2 |
| bars | 2 |
| ba | 2 |
| gallego | 2 |
| reimbursement | 2 |
| eo | 2 |
| uk | 2 |
| swex | 2 |
| presents | 2 |
| diabetes | 2 |
| severely | 2 |
| psummit | 2 |
| refers | 2 |
| conflicts | 2 |
| reflects | 2 |
| index | 2 |
| figures | 2 |
| relapsing | 2 |
| feagan | 2 |
| sahuquillo | 2 |
| aap | 2 |
| detailed | 2 |
| ceballos | 2 |
| example | 2 |
| miguel | 2 |
| guarino | 2 |
| confirmations | 2 |
| mdbgn | 2 |
| matched | 2 |
| urys | 2 |
| nuclear | 2 |
| becomes | 2 |
| employee | 2 |
| opinion | 2 |
| carlos | 2 |
| china | 2 |
| gov | 2 |
| meanwhile | 2 |
| elston | 2 |
| qyi | 2 |
| children | 2 |
| daniel | 2 |
| vulnerability | 2 |
| neighborhoods | 2 |
| dengue | 2 |
| emerging | 2 |
| janus | 2 |
| improve | 2 |
| broad | 2 |
| microneedle | 2 |
| little | 2 |
| preparation | 2 |
| completed | 2 |
| changes | 2 |
| academia | 2 |
| wk | 2 |
| supplies | 2 |
| design | 2 |
| granulocyte | 2 |
| evidences | 2 |
| promote | 2 |
| occurs | 2 |
| call | 2 |
| importance | 2 |
| organizations | 2 |
| recently | 2 |
| courses | 2 |
| rheumatoid | 2 |
| developed | 2 |
| debate | 2 |
| transcriptome | 2 |
| uniforms | 2 |
| various | 2 |
| basic | 2 |
| allow | 2 |
| biopsy | 2 |
| histopathological | 2 |
| none | 2 |
| division | 2 |
| strengthen | 2 |
| gap | 2 |
| cardiac | 2 |
| background | 2 |
| estebaranz | 2 |
| directly | 2 |
| humanity | 2 |